ストックスクリーナーアプリを入手
3.19
8.14%
0.24
アフターアワーズ：
3.40
0.21
+6.58%
前日終値:
$2.95
開ける：
$3.03
24時間の取引高:
267.49K
Relative Volume:
0.09
時価総額：
$8.65M
収益：
$556.00K
当期純損益:
$-5.28M
株価収益率:
-0.1833
EPS:
-17.4
ネットキャッシュフロー:
$-6.23M
1週間 パフォーマンス:
-7.00%
1か月 パフォーマンス:
+52.63%
6か月 パフォーマンス:
+39.91%
1年 パフォーマンス:
-24.94%
1日の値動き範囲:
$2.8345
$3.43
1週間の範囲:
$2.80
$3.79
52週間の値動き範囲:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
名前
Cyclerion Therapeutics Inc
セクター
電話
617-621-7722
住所
301 BINNEY STREET, CAMBRIDGE, MA
CYCN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
3.19 | 8.65M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-20 | 開始されました | Truist | Buy |
| 2021-09-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 開始されました | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc (CYCN) 最新ニュース
Cyclerion Therapeutics (NASDAQ: CYCN) Amends License Agreement with Akebia Therapeutics and Generates Revenues for GrowthOn December 17, 2024, Cyclerion Therapeutics, Inc. filed an 8-K SEC Filing which detailed significant developments in its b - Defense World
Cyclerion advances growth strategy with new agreements - Investing.com
Cyclerion Therapeutics Secures Funding and Expands CNS Focus - TipRanks
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewswire
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Head to Head Survey: Cyclerion Therapeutics (NASDAQ:CYCN) vs. scPharmaceuticals (NASDAQ:SCPH) - Defense World
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update - Defense World
3 US Penny Stocks With Market Caps Under $100M - Simply Wall St
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations - Investing.com Canada
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Stock market news: Cyclerion Therapeutics +280.50%, Cross Country Healthcare +62.01% among top gainers during mid day trading - Business Upturn
Stock market news: Relmada Therapeutics plunged by 75.54% while Cyclerion Therapeutics surged by 280.12% during mid day trading - Business Upturn
Stock market today: Cyclerion Therapeutics +343.79%, Cross Country Healthcare +63.04% among top gainers in early trading - Business Upturn
Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading - Business Upturn
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations By Investing.com - Investing.com South Africa
CYCN (Cyclerion Therapeutics) 3-Year EBITDA Growth Rate : 57.30% (As of Sep. 2024) - GuruFocus.com
CYCN (Cyclerion Therapeutics) GF Value Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclerion stock hits 52-week low at $1.55 amid market challenges - Investing.com Canada
Cyclerion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Head-To-Head Analysis: Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday - Quantisnow
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewswire
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors - Yahoo Finance
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement - GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer - Business Wire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results - Yahoo Finance
BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus - BioSpace
Cyclerion Therapeutics Inc (CYCN) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):